Information Provided By:
Fly News Breaks for March 20, 2019
CYTK
Mar 20, 2019 | 10:47 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Cytokinetics and raised his price target on shares to $13 from $12 after Cytokinetics and its partners announced that omecamtiv mecarbil has passed a futility analysis in the Phase III GALACTIC-HF trial, which will continue enrolling ~8,000 HFrEF patients. The analyst anticipates an interim efficacy analysis in 2020, prior to final data likely in 2021.
News For CYTK From the Last 2 Days
There are no results for your query CYTK
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.